Giredestrant vs Tamoxifen (Soltamox)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Giredestrant
Marketed by Roche
NCT04546009 · Phase 3 · active, not recruiting
This was a large (n=992), randomized, double-blind, active-controlled phase 3 trial using progression-free survival, a hard clinical endpoint, as its primary measure -- a strong design overall. However, the reported result showed only a numerical trend favoring giredestrant that did not reach statistical significance, so the trial does not provide confirmed evidence of benefit despite its rigorous design.
Next expected readout: July 2027 · NCT03332797 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)): persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. (missed)
Result source: NCT04546009
Tamoxifen (Soltamox)
Marketed by Mayne Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04174352 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Giredestrant | Tamoxifen (Soltamox) |
|---|---|---|
| PFS, median | —Trial running · NCT06065748 | 20.2 vs 15.6vs Endocrine TherapyNCT006019002 other results
|
| OS, median | —Trial running · NCT06065748 | 47.2 vs 43.9vs Endocrine TherapyNCT006019001 other result
|
| ORR | —Trial running · NCT06065748 | 30%bNCT02668666 |
| Clinical benefit rate | —Trial running · NCT06065748 | 64%bNCT02668666 |
PFS, median
- Giredestrant
- —Trial running · NCT06065748
- Tamoxifen (Soltamox)
- 20.2 vs 15.6vs Endocrine TherapyNCT00601900
2 other results
- 5 NCT03045653
- 9.1 NCT02668666
OS, median
- Giredestrant
- —Trial running · NCT06065748
- Tamoxifen (Soltamox)
- 47.2 vs 43.9vs Endocrine TherapyNCT00601900
1 other result
- 18.8 NCT02913430
ORR
- Giredestrant
- —Trial running · NCT06065748
- Tamoxifen (Soltamox)
- 30%bNCT02668666
Clinical benefit rate
- Giredestrant
- —Trial running · NCT06065748
- Tamoxifen (Soltamox)
- 64%bNCT02668666
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Giredestrant: 4 of 5 rows · Tamoxifen (Soltamox): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Giredestrant | Tamoxifen (Soltamox) |
|---|---|---|
| Ki67 absolute change · percentage points | -14.5% (n=40) vs -10% (n=44) Tamoxifen @ 2.14wka,b,c NCT05659563 · Phase 2 · registry result, not featured evidence | -3.4% (n=9) vs -5.1% (n=9) Tamoxifen Citratea,b,c NCT00952731 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 8.7%d NCT05659563 · Phase 2 · registry result, not featured evidence | 0%d NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results0.1% NCT00036270 · Phase 3 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 99.2% NCT01124695 · Phase 2 · registry result, not featured evidence 10.7%TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 63.2% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 11.4% NCT02806544 · Phase 2 · registry result, not featured evidence 0% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT01027416 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —d NCT05659563 · Phase 2 · registry result, not featured evidence | —d NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results— NCT00036270 · Phase 3 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence 8.9% NCT01124695 · Phase 2 · registry result, not featured evidence —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —high dose NCT03045653 · Phase 2 · registry result, not featured evidence 10.5% NCT00118157 · Phase 2 · registry result, not featured evidence · combination — NCT02806544 · Phase 2 · registry result, not featured evidence — NCT00365599 · Phase 2 · registry result, not featured evidence · combination — NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination — NCT02913430 · Phase 1 · registry result, not featured evidence · combination — NCT01027416 · Phase na · registry result, not featured evidence |
| Serious AEs | 0%d NCT05659563 · Phase 2 · registry result, not featured evidence | 28.7%d NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results17.1% NCT00036270 · Phase 3 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 24.6% NCT01124695 · Phase 2 · registry result, not featured evidence —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 3.6%TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 100% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 0% NCT02806544 · Phase 2 · registry result, not featured evidence 9.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 0% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 0% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0% NCT01027416 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | d arthralgia 9.5% hot flush 9.5% fatigue 7.1% NCT05659563 · Phase 2 · registry result, not featured evidence | d arthralgia 70.3% hypertension 59% proteinuria 47.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 11 more resultshot flush 31.3% arthralgia 23.8% fatigue 16.4% NCT00036270 · Phase 3 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence fatigue 14.8% back pain 13.9% nausea 11.5% NCT01124695 · Phase 2 · registry result, not featured evidence nausea 100% NCT02988986 · Phase 2 · registry result, not featured evidence · combination anemia 36.8% nausea 36.8% anorexia 31.6% NCT00118157 · Phase 2 · registry result, not featured evidence · combination fatigue - grade 2 18.6% nausea - grade 2 18.6% anorexia/weight loss - grade 2 16.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination hot flashes 58.3% pain 41.7% pain: breast 41.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination arthralgia 33.3% back pain 33.3% headache 33.3% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination blood and lymphatic system disorders - other 50% hypertension 50% neutrophil count decreased 50% NCT02913430 · Phase 1 · registry result, not featured evidence · combination headache 32.1% (placebo 0%) night sweats 32.1% (placebo 0%) irritability 28.6% (placebo 0%) NCT01027416 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Giredestrant
Tamoxifen (Soltamox)
show 1 more result
show 2 more results
show 1 more result
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Giredestrant's landscape · Tamoxifen (Soltamox)'s landscape